Is There a Difference in Occurrence of Complications Between Adults With Hemoglobin SS and Hemoglobin SC Disease: An Extended Systematic Review.

Eur J HaematolJun 15, 2026 (epub)
Clinical ResearchHematologyOpen access

Martijn van der Meer, Kim Velsink, Wing H Tong et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined complications in adults with Hemoglobin SS (HbSS) and Hemoglobin SC (HbSC) disease, analyzing 31 studies. It found that HbSS patients experience more frequent vaso-occlusive crises (VOCs), while HbSC patients have a higher prevalence of chronic complications, particularly in ocular and pulmonary systems. The review highlights the differing clinical courses of these genotypes.

Key findings

  • HbSS patients experience more frequent vaso-occlusive crises compared to HbSC patients.
  • Chronic complications, especially in ocular and pulmonary systems, are more prevalent in HbSC patients.
  • Both genotypes face progressive organ damage due to recurrent ischemic injury and inflammation.

Why it matters

Understanding the differences in complications between HbSS and HbSC can inform clinical management and monitoring strategies for patients with sickle cell disease, potentially improving patient outcomes.

Source

PubMed · PMID 42297565Free full text on PubMed Central

Published in Eur J Haematol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.